Reuters Health Information
Radiotherapy no better than sorafenib for inoperable liver cancer
Last Updated: 2017-11-10
By David Douglas
Radiotherapy no better than sorafenib for inoperable liver cancer
Last Updated: 2017-11-10
By David Douglas
NEW YORK (Reuters Health) - Selective internal radiotherapy (SIRT) with yttrium-90 resin microspheres does not prolong survival compared to sorafenib in patients with advanced hepatocellular carcinoma not eligible for curative treatment, according to French researchers.
But lead author Dr. Valerie Vilgrain of Hopital Beaujon, in Clichy told Reuters Health by email, "We did observe a better tolerance a better quality of life and a higher tumor control."
The study, an open-label phase 3 trial conducted at 25 centers specializing in liver diseases, was published online October 26 in The Lancet Oncology. Participants had to be at least 18 years old and have a life expectancy greater than three months.
In all, 467 patients were randomly assigned to receive continuous oral sorafenib (400 mg twice daily) or SIRT with yttrium-90-loaded resin microspheres two to five weeks after randomization. Median follow-up was about 28 months.
In the intention-to-treat population, median overall survival with sorafenib (9.9 months) was not significantly greater than the 8.0 months seen with SIRT (P=0.18). In per-protocol analysis, OS was 9.9 months in both groups.
But lead author Dr. Valerie Vilgrain of Hopital Beaujon, in Clichy told Reuters Health by email, "We did observe a better tolerance a better quality of life and a higher tumor control."
The study, an open-label phase 3 trial conducted at 25 centers specializing in liver diseases, was published online October 26 in The Lancet Oncology. Participants had to be at least 18 years old and have a life expectancy greater than three months.
In all, 467 patients were randomly assigned to receive continuous oral sorafenib (400 mg twice daily) or SIRT with yttrium-90-loaded resin microspheres two to five weeks after randomization. Median follow-up was about 28 months.
In the intention-to-treat population, median overall survival with sorafenib (9.9 months) was not significantly greater than the 8.0 months seen with SIRT (P=0.18). In per-protocol analysis, OS was 9.9 months in both groups.
SOURCES: http://bit.ly/2zNoS8y and http://bit.ly/2hoUauS
Lancet Oncol 2017.
Lancet Oncol 2017.
No comments:
Post a Comment